Marie O’Farrell

First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors

Gerald S. Falchook, Jeffrey R. Infante, Hendrik‐Tobias Arkenau et al. · EClinicalMedicine · 2021 · 250 citations · Full text

TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial

Rohit Loomba, Rizwana Mohseni, Kathryn Jean Lucas et al. · Gastroenterology · 2021 · 204 citations · Full text

p21-Activated Kinase 1 Is Required for Efficient Tumor Formation and Progression in a Ras-Mediated Skin Cancer Model

Hoi Yee Chow, Adrian M. Jubb, Jennifer N. Koch et al. · Cancer Research · 2012 · 160 citations · Full text

Tumor Regression, Ras Genes, Dermatology +17

Therapeutic efficacy of FASN inhibition in preclinical models of HCC

Haichuan Wang, Yi Zhou, Hongwei Xu et al. · Hepatology · 2022 · 115 citations · Full text

FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models

Marie O’Farrell, G M Duke, R. Webster Crowley et al. · Scientific Reports · 2022 · 89 citations · Full text

Immunology, Cell Death, Fatty Liver Disease +21